8-K: Tenaya Therapeutics Lifts FDA Hold, Reports Positive Gene Therapy Data

Tenaya Therapeutics announced the FDA lifted the clinical hold on its MyPEAK-1 trial for TN-201 and reported positive interim data from the RIDGE-1 trial for TN-401.

Summary

• The U.S. Food and Drug Administration (FDA) has removed the clinical hold on the MyPEAK-1 Phase 1b/2a clinical trial of TN-201 gene therapy, addressing all concerns related to patient monitoring and immunosuppression management.
• The company intends to resume dosing for MyPEAK-1 once protocol changes have been implemented at trial sites and expects to present two-year Cohort 1 and one-year Cohort 2 data in the first half of 2026.
• Interim data from Cohort 1 of the RIDGE-1 Phase 1b/2 clinical trial for TN-401 gene therapy showed it was generally well tolerated at the 3E13 vg/kg dose, with no dose-limiting toxicities observed.
• TN-401 demonstrated robust transduction to the heart, with vector copy numbers of 3.4 and 5 per genome in two patients, and increased PKP2 protein levels by a mean of 10% from baseline to Week 8 in these patients.
• Clinically meaningful reductions in electrical instability were observed in two of three patients with more than six months of follow-up, including a 46% decrease in premature ventricular contractions (PVCs) for Patient 1 and an 89% decrease for Patient 2, with Patient 2's non-sustained ventricular tachycardias (NSVTs) burden dropping from 78 counts to zero.
• No new serious adverse events related to TN-401 have been reported in Cohort 2, where dosing of three patients at the 6E13 vg/kg dose is complete, and all Cohort 1 patients have tapered off prophylactic immunosuppressive medicines.

Sentiment

Score: 8

Explanation: The lifting of an FDA clinical hold is a significant positive, removing a major overhang. Coupled with promising interim efficacy and safety data for another key gene therapy candidate, TN-401, the overall sentiment is strongly positive. The observed reductions in arrhythmia burden and successful protein expression are encouraging for the long-term potential of the pipeline.

Positives

• The FDA lifted the clinical hold on the MyPEAK-1 trial for TN-201, indicating successful resolution of regulatory concerns and allowing the trial to resume dosing.
• TN-201 has been generally well tolerated, and the MyPEAK-1 Data and Safety Monitoring Board (DSMB) endorsed continued enrollment of the trial following a review of all available safety data.
• TN-401 was well tolerated at the 3E13 vg/kg dose in the RIDGE-1 trial, with no dose-limiting toxicities observed and adverse events generally mild, asymptomatic, and manageable.
• Robust transduction and expression of TN-401 were detected in all patients within the first eight weeks, with significant increases in PKP2 protein levels (mean 10% increase in two patients) confirmed by rigorous methods.
• Clinically meaningful improvements in electrical instability (reductions in PVCs by 46% and 89%, and elimination of NSVTs) were observed in two of three patients in the RIDGE-1 trial with sufficient follow-up.
• No incidents of thrombotic microangiopathy or cardiotoxicities were observed with TN-401, and no implantable cardioverter-defibrillator (ICD) shocks or arrhythmias associated with the therapy occurred.
• All Cohort 1 patients in the RIDGE-1 trial have successfully tapered off prophylactic immunosuppressive medicines.
• The company does not expect the MyPEAK-1 clinical hold to impact data milestones or development timelines for TN-201.

Negatives

• Patient 3 in the RIDGE-1 trial did not show meaningful changes in PVCs or NSVTs as of the data cut-off, which was less than six months following treatment with TN-401.
• Change from baseline in PKP2 protein levels for Patient 3 appeared slightly lower than baseline despite having the highest levels of TN-401 mRNA expression, though this was attributed to inherent variability in biopsy sampling.
• A Grade 1 incidence of elevated cardiac troponin levels was categorized as a serious adverse event (SAE) for TN-401, although it was transient, asymptomatic, and deemed an SAE only due to inpatient monitoring.

Risks

• The availability of RIDGE-1 data at the referenced time may vary.
• The timing and progress of RIDGE-1 and MyPEAK-1 clinical trials are subject to uncertainties.
• There is a potential for TN-201 or TN-401 to fail to demonstrate safety and/or efficacy in clinical testing.
• Clinical trial results may differ from preclinical, interim, preliminary, or expected results.
• The company's ability to enroll and maintain patients in clinical trials, including RIDGE-1 and MyPEAK-1, is crucial.
• Risks are associated with the process of discovering, developing, and commercializing drugs that are safe and effective for human therapeutics and operating as an early-stage company.
• The company must maintain continuing compliance with applicable legal and regulatory requirements.
• The company's ability to raise any additional funding it will need to continue to pursue its product development plans is a factor.
• Reliance on third parties for various aspects of development and commercialization poses risks.
• Manufacturing, commercialization, and marketing capabilities and strategy are subject to challenges.
• The loss of key scientific or management personnel could impact operations.
• Competition in the industry in which the company operates is a constant factor.
• The company's ability to obtain and maintain intellectual property protection for its product candidates is essential.
• General economic and market conditions can affect the company's performance.
• The FDA and/or other regulatory agencies could conclude at any time that TN-201 or TN-401 may not have an appropriate risk/benefit profile.

Future Outlook

Tenaya Therapeutics plans to resume dosing for the MyPEAK-1 trial for TN-201 once protocol changes are implemented and expects to present two-year Cohort 1 and one-year Cohort 2 data in the first half of 2026. For the RIDGE-1 trial of TN-401, the company anticipates presenting one-year Cohort 1 data and early Cohort 2 data in the first half of 2026. The company believes these developments will not impact data milestones or development timelines for TN-201 and looks forward to building on the momentum of the positive interim TN-401 data.

Management Comments

• "We are excited by the strength of the data for TN-401 at this relatively early timepoint in the RIDGE-1 trial. Less than a year after dosing, initial data indicate a promising safety profile, consistent transduction of the gene therapy in cardiomyocytes and RNA and protein expression, and meaningful reductions in PVCs and NSVTs, well-established risk factors for dangerous sustained arrhythmias." Whit Tingley, M.D., Ph.D., Tenaya's Chief Medical Officer.
• "These findings are an important milestone in TN-401's development and we're eager to build on this momentum as we continue monitoring patients in Cohort 1 and Cohort 2." Whit Tingley, M.D., Ph.D., Tenaya's Chief Medical Officer.
• "We extend our heartfelt gratitude to the patients and investigators involved in the RIDGE-1 clinical trial and our RIDGE natural history study of PKP2-associated ARVC. Their continued support and dedication have been instrumental in achieving the substantial progress we've made thus far." Dr. Tingley.

Industry Context

The lifting of the FDA clinical hold for TN-201 and the positive interim data for TN-401 position Tenaya Therapeutics favorably within the competitive gene therapy landscape for rare cardiovascular diseases. These developments underscore the growing potential of AAV9-based gene therapies to address underlying genetic causes of heart conditions like HCM and ARVC, where current treatments are largely symptomatic. Successful progression in these trials could validate Tenaya's platform and contribute to a new paradigm in treating inherited cardiomyopathies, potentially attracting further investment and partnerships in the gene therapy sector.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress and regulatory resolution could lead to increased investor confidence and potential share price appreciation.
• Patients: The progress in TN-201 and TN-401 trials offers hope for new, potentially curative treatments for severe genetic heart diseases (HCM and ARVC) that currently lack disease-modifying therapies.
• Employees: Positive clinical developments can boost morale and validate the company's research and development efforts.
• Regulatory Authorities: Successful resolution of the clinical hold demonstrates effective collaboration with the FDA and adherence to regulatory requirements.

Next Steps

• Implement protocol changes at MyPEAK-1 clinical sites to resume dosing for TN-201.
• Present two-year Cohort 1 and one-year Cohort 2 data for TN-201 in the first half of 2026.
• Continue monitoring patients in Cohort 1 and Cohort 2 of the RIDGE-1 trial for TN-401.
• Collect and analyze a second post-dose biopsy from Patient 3 in RIDGE-1 at Week 52 per protocol.
• Present one-year Cohort 1 data and early Cohort 2 data for TN-401 in the first half of 2026.

Key Dates

Recommendation

The lifting of the FDA clinical hold on TN-201 removes a significant regulatory hurdle and de-risks a key pipeline asset. Simultaneously, the positive interim data for TN-401, showing robust transduction, increased protein expression, and clinically meaningful reductions in arrhythmia burden, provides strong early validation for another gene therapy candidate. These combined developments suggest a favorable risk-reward profile, indicating significant progress in addressing the underlying causes of severe heart diseases with potentially curative therapies. The company's ability to resolve the hold swiftly and present encouraging data across two programs points to strong operational execution and scientific promise, making it a compelling investment opportunity.

Keywords

Tenaya Therapeutics, TNYA, Gene Therapy, Clinical Trial, FDA, Clinical Hold, MyPEAK-1, TN-201, Hypertrophic Cardiomyopathy, HCM, MYBPC3, RIDGE-1, TN-401, Arrhythmogenic Right Ventricular Cardiomyopathy, ARVC, PKP2, Cardiology, Biotechnology, Orphan Drug, Fast Track